FSUE Moscow Endocrine Plant became the winner of the National award in the area of import substitution “Priority-2017”, presenting the new medicinal product “Fentanyl transdermal therapeutic system 12,5/ 25/ 50/ 75/ 100 (µgr/h)".
On November 17, 2017, the 3rd ceremony took place at the Congress Centre of the Chamber of Commerce and Industry of the Russian Federation, in the area of import substitution “PRIORITY-2017”. FSUE Moscow Endocrine Plant became the winner of the National award in nomination of “Priority-Pharma”, presenting the new medicinal product “Fentanyl transdermal therapeutic system 12,5/ 25/ 50/ 75/ 100 µgr/h)". As part of the competition, 422 applications were considered from 374 enterprises of the country. Qualitative award was presented to the best enterprises that achieved the highest success in import substitution.
The award ceremony was attended by the Enterprise’s employees - Deputy Operational Director, Lukashina Irina Viktrovna and the Head of the preclinical, clinical research and pharmacovigilance department, Irina Kotelnikova.
The Enterprise also submitted Trimucamide, eye drops, 0.5% and 1% to participate in the competition.
The medicinal products submitted for participation in the competition was registered in 2017 as part of the national import substitution policy in the pharmaceutical industry and the Federal target program “Development of pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond”.
“FENTANYL transdermal therapeutic system 12,5/ 25/ 50/ 75/ 100 µgr/h” produced by FSUE Moscow Endocrine Plant is the first home produced generic; there are no counterparts of this product produced in Russia. The product is intended for chronic pain non-invasive therapy. Fully complies with the tasks of the action plan (“road map”) implementation - “Promotion of the availability of narcotic drugs and psychotropic substances for medical use” (“road map”).
TROPICAMIDE, eye drops is the first home-produced generic. Intended for using in Ophthalmology. The Enterprise can fully cover demands in the product in the Russian Federation.
Comment type is not specified in the component properties.